News

On May 23, at the European Medicines Verification Organisation’s (EMVO) General Assembly meeting, the NMVO Observers within EMVO’s Board for 2024 from the National Medicines Verification Organizations (NMVOs) were approved. Latvian Medicines Verification Organisation (LZVO) and its Chairwoman of the Board Inese Erdmane were re-elected as observers for the second consecutive year, representing the small countries group.

The Latvian Medicines Verification System (LZVS) was updated to release 4.0 on May 21. The system is fully functional, and all updated data is available.

The Latvian Medicines Verification System (LZVS) will be updated to release 4.0 on May 21 this year. The installation of the release is scheduled for overnight starting at 21:00, during which temporary interruptions in system operation are possible.

The European Commission has published a new version of the Questions & Answers (Q&A) document on “Safety Features for Medicinal Products for Human Use (V.21)”.

In the event of a recall of a batch, withdrawal of a product from the market or a case of stolen packages, the marketing authorisation holder (MAH) should perform appropriate decommissioning transactions in the EMVS system for the affected markets, reminds the Latvian Medicines Verification Organization (LZVO).

The European Medicines Verification Organisation (EMVO) has launched the EMVS Community Newsletter - edition April 2024. This month, newsletter focusing on Data Quality, featuring insights from EMVO, the Dutch NMVO, Accord Healthcare, and end-user perspectives from the healthcare sector.